Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In Science Journals.

Science (New York, N.Y.)·2026

Same author

Designer binders.

Science signaling·2026

Same author

Cholinergic signals and antibodies.

Science signaling·2026

Same author

Editorial expression of concern.

Science signaling·2026

Same author

Editorial retraction.

Science signaling·2026

Same author

SIRT2 versus Lck.

Science signaling·2026

Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026

Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026

Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026

Same journal

Cerebral Artery Pulsatility, Premorbid Blood Pressure, and Small Vessel Disease on Brain Imaging: A Population-Based Study.

Neurology·2026

Same journal

Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.

Neurology·2026

Same journal

What is the Relevance of Neuron-Tumor Interactions in Malignant CNS Tumors?

Neurology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Redefining functionality and treatment efficacy in multiple sclerosis.

John F Foley¹, David W Brandes

¹Rocky Mountain Neurological Associates, Salt Lake City, UT, USA.

|June 10, 2009

Summary

This summary is machine-generated.

Physicians often overlook multiple sclerosis (MS) patients' quality of life (QoL) impacts. Integrating QoL assessments alongside traditional measures like the Expanded Disability Status Scale is crucial for holistic MS care.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 22, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

Neurology
Clinical Medicine
Patient-Reported Outcomes

Background:

Multiple sclerosis (MS) understanding has advanced, yet discrepancies persist between physician and patient perceptions of disease impact.
Current MS assessment tools and clinical trial designs may not fully capture the patient experience.

Purpose of the Study:

To examine deficiencies in current MS assessment practices and clinical trial designs.
To highlight the underrecognized impact of MS on patient quality of life (QoL).
To advocate for the independent assessment of QoL in MS management.

Main Methods:

Review of current practices in MS assessment and clinical trial design.
Analysis of commonly used measurement techniques (e.g., Expanded Disability Status Scale, MRI).
Identification and discussion of validated QoL measures relevant to MS.

Main Results:

Commonly used MS assessment tools (Expanded Disability Status Scale, MRI) show minimal clinical awareness of QoL impacts.
QoL elements (cognition, fatigue, pain, visual disturbances, depression, social function) significantly affect MS patients, often correlating poorly with traditional metrics.
Validated QoL measures exist and can be incorporated into routine patient care.

Conclusions:

QoL assessment should be independent of traditional measures like the Expanded Disability Status Scale and MRI.
Expanding definitions of
functionality
and
efficacy
to include QoL is essential for a holistic view of MS.
Integrating QoL assessments can improve patient management and clinical trial outcomes in MS.